gabapentin 600 mg + gabapentin 1200 mg + gabapentin 600 mg and oxycodone HCl 20 mg + gabapentin 1200 mg and oxycodone HCl 20 mg + oxycodone HCl 20 mg + placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Abuse Potential
Conditions
Abuse Potential
Trial Timeline
Apr 30, 2021 โ Dec 31, 2021
NCT ID
NCT05319756About gabapentin 600 mg + gabapentin 1200 mg + gabapentin 600 mg and oxycodone HCl 20 mg + gabapentin 1200 mg and oxycodone HCl 20 mg + oxycodone HCl 20 mg + placebo
gabapentin 600 mg + gabapentin 1200 mg + gabapentin 600 mg and oxycodone HCl 20 mg + gabapentin 1200 mg and oxycodone HCl 20 mg + oxycodone HCl 20 mg + placebo is a approved stage product being developed by Viatris for Abuse Potential. The current trial status is completed. This product is registered under clinical trial identifier NCT05319756. Target conditions include Abuse Potential.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05319756 | Approved | Completed |
Competing Products
15 competing products in Abuse Potential
Other Products from Viatris
Revefenacin + Tiotropium + Revefenacin Placebo + Tiotropium PlaceboApproved
82
PregabalinApproved
82
Imiquimod + DiclofenacApproved
82
gabapentin 600 mg + gabapentin 1200 mg + gabapentin 1800 mg + diazepam 20 mgApproved
82
Sulfamylonยฎ For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsApproved
82